Lisata Therapeutics
LSTA
28 hedge funds and large institutions have $2.85M invested in Lisata Therapeutics in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.
279% more call options, than puts
Call options by funds: $129K | Put options by funds: $34K
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
9% more capital invested
Capital invested by funds: $2.62M → $2.85M (+$231K)
4% more funds holding
Funds holding: 27 → 28 (+1)
0.03% more ownership
Funds ownership: 0.5% → 0.53% (+0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$88.7K |
| 2 |
STA
Summit Trail Advisors
New York
|
+$77.7K |
| 3 |
WB
WesBanco Bank
Wheeling,
West Virginia
|
+$43.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$24.5K |
| 5 |
Morgan Stanley
New York
|
+$21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$27K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$6.44K |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$5K |
| 4 |
BlackRock
New York
|
-$4.67K |
| 5 |
WOC
West Oak Capital
Westlake Village,
California
|
-$356 |
LSTA Hedge Fund Activity: Q1 2019 in Review
28 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q1 2019, worth a combined $2.85M — up 8.8% from $2.62M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new LSTA positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $88.7K. The largest seller was Deutsche Bank, cutting an estimated $27K.
- 28 institutional investors held Lisata Therapeutics (LSTA) as of Q1 2019, up from 27 in Q4 2018.
- Funds reported $2.85M of Lisata Therapeutics stock for Q1 2019, up 8.8% quarter-over-quarter.
- 4 funds opened new Lisata Therapeutics positions in Q1 2019 and 3 closed out, a net change of +1 holder.
- The largest Lisata Therapeutics buyer in Q1 2019 was Renaissance Technologies, an estimated $88.7K added.
- The largest Lisata Therapeutics seller in Q1 2019 was Deutsche Bank, an estimated $27K sold.
Based on aggregated 13F filings for Q1 2019.